drugset / Trial / NCT04529096
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain
RandomizedParallel-groupDouble-blindTreatment
Summary
This study is being done to test the safety and efficacy of the study drug LY3016859 for the treatment of chronic low back pain. This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Timeline
- Start
- 2020-08-25
- Primary completion
- 2021-06-04
- Completion
- 2021-10-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fepixnebart | Monoclonal antibody | 500 mg | Intravenous |